Company Overview of Lentigen Corporation
Lentigen Corporation, a biologics company, engages in the development and commercialization of lentiviral gene delivery products for human diseases for therapeutic, vaccine, and bioproduction applications. The company’s product pipeline includes treatment for chronic lymphocytic leukemia, glioblastoma, melanoma, and hemophilia A; vaccine preclinical programs and vaccine candidates, including virus like particles vaccines that target pandemic and seasonal influenza, Hepatitis C virus infection, and HIV/AIDS; and protein therapeutics that include the production of erythropoietin and factor VIII. It also has various programs on various stem cell types, such as hematopoietic (or blood making) st...
910 Clopper Road
Suite 200 South
Gaithersburg, MD 20878
Founded in 2004
Key Executives for Lentigen Corporation
Chief Executive Officer and Director
President of Commercial Operations
Vice President of Corporate Development
Vice President of Vector Development
Compensation as of Fiscal Year 2012.
Lentigen Corporation Key Developments
Lentigen Corporation Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme
Feb 13 13
Lentigen Corporation announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives. LG631-CD34 is currently being evaluated in a NIH grant-funded Phase I clinical trial at University Hospitals (UH) Case Medical Center under the leadership of Stanton Gerson, MD, Director of the Seidman Cancer Center at UH Case Medical Center, Director of the National Center for Regenerative Medicine and Case Comprehensive Cancer Center and Asa, Patricia Shiverick - Jane Shiverick (Tripp) Professor of Hematological Oncology at Case Western Reserve University School of Medicine and Andrew Sloan MD, Associate Professor & Vice-Chairman, Department of Neurological Surgery and the Peter D. Cristal Chair of Neurosurgical Oncology at Case Western Reserve University School of Medicine, Director, Brain Tumor and Neuro-Oncology Center, UH Case Medical Center and a member of the Case Comprehensive Cancer Center.
Lentigen Corporation Presents at EBD Group, Inc.'s Biotech Showcase 2012, Jan-10-2012 01:45 PM
Dec 14 11
Lentigen Corporation Presents at EBD Group, Inc.'s Biotech Showcase 2012, Jan-10-2012 01:45 PM. Venue: Parc 55 Wyndham San Francisco Union Square, 55 Cyril Magnin Street, San Francisco, 94102, California, United States.
University Hospitals Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer
Dec 3 11
University Hospitals Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar. Approximately 17,000 Americans are diagnosed with glioblastoma every year and only 2% of them survive longer than five years, even with aggressive treatment. Glioblastoma (GBM) treatment generally begins with a surgical resection, followed by radiation therapy and then chemotherapy to destroy any remaining cancer cells. Temodar (temozolomide, Merck and Co. Inc.) is a standard treatment of glioblastoma, but dose-limiting bone marrow toxicity often accompanies such therapy. In this first-of-its-kind study, researchers are investigating if LG631 can potentially improve tolerance and effectiveness of chemotherapy for GBM by preventing damage to bone marrow. The study will evaluate the safety of this treatment and its potential to enhance current GBM treatments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|